3 results
Approved WMOPending
The objectives of this study are to determine the safety and efficacy of IW-9179administered to patients with functional dyspepsia (FD), with and without concomitant protonpump inhibitor (PPI) administration.
Approved WMOPending
To investigate the safety and efficacy of quizartinib in children and adolescents with newly diagnosed FLT3-ITD positive AML with normal NPM1.
Approved WMORecruiting
The goal of the fenebrutinib development program in MS is to evaluate the benefits and risks of fenebrutinib treatment across the spectrum of patients with MS. Based on the existing toxicology, pharmacology, and clinical experience with fenebrutinib…